Therapeutic potential of oral factor xa inhibitors

New England Journal of Medicine

Volumn 363, Issue 26, 2010, Pages 2559-2561

  Hylek, Elaine M ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIFUNGAL AGENT; ANTIVITAMIN K; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; EDOXABAN; ENOXAPARIN; HEPARIN; PROTEINASE INHIBITOR; RIVAROXABAN; WARFARIN; YM 150;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EDITORIAL; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; PRIORITY JOURNAL; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 78650622643     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1012149     Document Type: Editorial

References (10)

1. Anderson FA Jr, Wheeler HB. Physician practices in the management of venous thromboembolism: a community-wide survey. J Vasc Surg 1992;16:707-14.
2. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107: Suppl 1: I4-I8.
3. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
4. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-98.
5. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-34.
6. Med Watch safety alerts: Coumadin tablets (warfarin sodium tablets, USP) crystalline. Silver Spring, MD: Food and Drug Administration, 2006. (http://www.fda.gov/medwatch/safety/2006/coumadin-medguide.pdf.)
7. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22.
8. Mahaffey KW, Fox KAA. Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). (http://sciencenews. myamericanheart.org/pdfs/ROCKET-AF-pslides.pdf.)
9. AVERROES study of investigational agent apixaban closes early due to clear evidence of efficacy. BusinessWire. June 10, 2010. (http://www. businesswire.com/news/home/20100610006606/en/AVERROES-Study-Investigational- Agent-Apixaban-Closes-Early.)
10. APPRAISE-2 study with investigational compound apixaban in acute coronary syndrome discontinued. BusinessWire. November 18, 2010. (www.businesswire.com/ news/bms/20101118007161/en/APPRAISE-2-Study-Investigational-Compound-Apixaban- Acute-Coronary.)